What Is the Treatment for Lambert-Eaton Myasthenic Syndrome?

Clinical Scenario

This protocol covers first-line symptomatic management of Lambert-Eaton myasthenic syndrome (LEMS). It defines a structured pharmacological approach for patients requiring initial treatment.

Treatment Approach

First-line symptomatic therapy for LEMS is built around a combination of oral agents, with amifampridine as a central component used alongside a second agent. A defined titration and dosing framework guides the regimen — the complete algorithm, combination details, and escalation steps are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/17562864231213240

In LEMS, symptomatic therapy must be with amifampridine or 3,4-DAP and pyridostigmine.
Based on expert knowledge, pyridostigmine may be given in combination with amifampridine.

View source ↗